Literature DB >> 23072848

Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital.

Ameera Khalam1, Chandrasekhar Dilip, Cholamugath Shinu.   

Abstract

BACKGROUND: Many drugs are available for the treatment of diabetes mellitus and are sometimes prescribed in combination. Irrational use of drugs is increasing expenditure and strain on health budgets. The aim of this study was to determine patient demographic characteristics, analyze prescription patterns of antidiabetic drugs, distribution of complications of diabetes, distribution of co-existing illnesses, distribution of common symptoms of diabetes and distribution of adverse drug reactions.
METHODS: A study was carried out for 11 months in diabetic inpatients in the General Medicine Department. Data of 200 patients were collected and evaluated.
RESULTS: The pattern of drug prescription in diabetes shows that insulin (80.5%) was most frequently prescribed followed by biguanides (23%), sulfonylureas (22.5%), thiazolidinediones (11%), dipeptidyl peptidase-IV (DPP-4) inhibitors (9.5%) and meglitinides (5.5%). The percentage of patients on diet control therapy was found to be 3%. Combination therapy was prescribed to 26.5% and monotherapy to 65% of patients; 47.5% of these patients were male and 52.5% were female. The most common co-existing illness was found to be hypertension (53.5%). In addition, 67% of patients had irregular blood sugar monitoring and the remaining 33% had regular (either 4 or 6 hourly) monitoring.
CONCLUSIONS: It is concluded that the prescribing trend is moving away from monotherapy with insulin and sulfonylureas and towards combination therapies. There is also a significant increase in prescriptions of newer oral antidiabetic drugs, such as DPP-4 inhibitors and insulin analogs. Most inpatients had their blood glucose checked irregularly and haphazardly by ward staff. This study strongly highlights the need for patient education or counseling on use of antidiabetic and concomitant drugs, monitoring of blood glucose and glycosylated hemoglobin (HbA1c) levels, diet control and correction of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072848     DOI: 10.1515/jbcpp-2012-0012

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  6 in total

Review 1.  Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

Authors:  Francisco J Pasquel; Maya Fayfman; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2019-07-29       Impact factor: 4.810

2.  Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: a cross-sectional retrospective study.

Authors:  Hasniza Zaman Huri; NorFarahen Selamat; Shireene Ratna Vethakkan
Journal:  Int J Endocrinol       Date:  2014-09-02       Impact factor: 3.257

Review 3.  Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.

Authors:  Sarayu A Pai; Nilima A Kshirsagar
Journal:  Indian J Med Res       Date:  2016-11       Impact factor: 2.375

4.  Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.

Authors:  Woh Yon Mak; Jivanraj R Nagarajah; Hannah Abdul Halim; Anitha Ramadas; Zulsairi Mohd Pauzi; Lay Ting Pee; Nirmala Jagan
Journal:  J Pharm Policy Pract       Date:  2020-06-18

Review 5.  Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices.

Authors:  Rodolfo J Galindo; Ketan Dhatariya; Fernando Gomez-Peralta; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2022-05-04       Impact factor: 5.430

Review 6.  Management of diabetes mellitus type-2 in the geriatric population: Current perspectives.

Authors:  Sukhminder Jit Singh Bajwa; Vishal Sehgal; Sanjay Kalra; Manash Pratim Baruah
Journal:  J Pharm Bioallied Sci       Date:  2014-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.